Q-omics provides the consensus-scored C22orf24 profile across patient tissues and cancer cell-line models. C22orf24 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, C22orf24 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, C22orf24 RNA expression shows 16,853 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, LIHC, and TGCT as cancer lineages where C22orf24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C22orf24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C22orf24 survival associations across molecular data types. C22orf24 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C22orf24 RNA expression–survival associations across cancer types. High C22orf24 expression shows unfavorable associations in ACC and BLCA, but favorable associations in UCS, THYM, READ and BRCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for C22orf24 RNA expression.
This table summarizes C22orf24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for C22orf24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C22orf24 shows lower tumor expression in THCA and higher tumor expression in LIHC, HNSC, COAD, KIRP and CHOL. The LIHC box plot shows higher C22orf24 RNA expression in tumor versus normal tissue (log2 FC = +0.089, t-test p < 0.001).
This table shows molecular features associated with C22orf24 in patient tissues and cancer cell lines. In patient samples, C22orf24 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, C22orf24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
